Adult growth hormone deficiency in CEE region: Heterogeneity of the patient pathway
Language English Country Scotland Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
PubMed
31234055
DOI
10.1016/j.ghir.2019.06.001
PII: S1096-6374(19)30026-7
Knihovny.cz E-resources
- Keywords
- Adult growth hormone deficiency (AGHD), CEE adult endocrinology advisory board, Central and Eastern Europe (CEE), Growth hormone replacement therapy (GHRT), Practice guidelines, Recombinant human growth hormone (rhGH),
- MeSH
- Adult MeSH
- Dwarfism, Pituitary diagnosis genetics therapy MeSH
- Hypopituitarism diagnosis genetics therapy MeSH
- Critical Pathways * MeSH
- Humans MeSH
- Human Growth Hormone deficiency MeSH
- Practice Guidelines as Topic standards MeSH
- Standard of Care * MeSH
- Check Tag
- Adult MeSH
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
- Names of Substances
- Human Growth Hormone MeSH
OBJECTIVES: Adult growth hormone deficiency (AGHD) is a rare disease characterised by abnormal body composition, reduced strength and exercise capacity and impaired psychological wellbeing. An advisory board of leading Central and Eastern European (CEE) endocrinologists was assembled to gain insights into the status of AGHD care in the CEE region. Topics of discussion included the position of adult hypopituitarism/AGHD in health system priorities, availability and affordability of treatments, awareness of AGHD, practice guidelines used in CEE countries and provisions for long-term care of patients. DESIGN: Prior to the meeting, the advisors were asked to summarise, using an itemised survey questionnaire, the usual standards of care for patients with AGHD in their country. At the meeting, the panel of experts discussed the findings and thereby elucidated similarities and differences among CEE countries; these were compared with international guideline-recommended practices for AGHD. RESULTS: All CEE countries involved reported having some type of infrastructure in place for care of patients with GHD transitioning from adolescence to adulthood. Most countries reported having at least one specialist centre for patients with AGHD. The main variations across the region included initial entry into healthcare systems, tests required to confirm AGHD diagnosis and medication reimbursement by health authorities. Most CEE countries relied on international society-led guidelines, while some countries have developed national guidelines. CONCLUSION: The CEE Adult Endocrinology Advisory Board meeting recognised considerable diversity in the care and patient pathways for AGHD across CEE countries. Additional work is needed to optimise care of patients with AGHD in the CEE region.
C Davila University of Medicine and Pharmacy National Institute of Endocrinology Bucharest Romania
Children's University Hospital Riga Stradin's University Riga Latvia
Clinical Center of Endocrinology and Gerontology Medical University Sofia Bulgaria
Department of Internal Medicine 1st Faculty of Medicine Charles University Prague Czech Republic
Department of Internal Medicine University Hospital of Comenius University Bratislava Slovakia
Faculty of Medicine University of Ljubljana Slovenia
Pfizer Innovative Health Brussels Belgium
References provided by Crossref.org